Correction: Physiological characterization of a novel PPAR pan agonist, 2-(4-(5,6-methylenedioxybenzo[d]thiazol-2-yl)-2-methylphenoxy)-2-methylpropanoic acid (MHY2013)

Hye Jin An; Bonggi Lee; Dae Hyun Kim; Eun Kyeong Lee; Ki Wung Chung; Min Hi Park; Hyoung Oh Jeong; Sung Min Kim; Kyoung Mi Moon; Ye Ra Kim; Seong Jin Kim; Hwi Young Yun; Pusoon Chun; Byung Pal Yu; Hyung Ryong Moon; Hae Young Chung

doi:10.18632/oncotarget.18922

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Physiological characterization of a novel PPAR pan agonist, 2-(4-(5,6-methylenedioxybenzo[d]thiazol-2-yl)-2-methylphenoxy)-2-methylpropanoic acid (MHY2013)

Hye Jin An, Bonggi Lee, Dae Hyun Kim, Eun Kyeong Lee, Ki Wung Chung, Min Hi Park, Hyoung Oh Jeong, Sung Min Kim, Kyoung Mi Moon, Ye Ra Kim, Seong Jin Kim, Hwi Young Yun, Pusoon Chun, Byung Pal Yu, Hyung Ryong Moon and Hae Young Chung _

PDF | How to cite

Oncotarget. 2017; 8:45030-45030. https://doi.org/10.18632/oncotarget.18922

Metrics: PDF 2818 views | ?

Present: The author name 'Sung Min Kim' is spelled incorrectly.

Correct: The proper spelling is 'Seong Min Kim'.

Original article: Oncotarget. 2017;8:16912-24. DOI:10.18632/oncotarget.14818.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18922

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Physiological characterization of a novel PPAR pan agonist, 2-(4-(5,6-methylenedioxybenzo[d]thiazol-2-yl)-2-methylphenoxy)-2-methylpropanoic acid (MHY2013)